The levels of serum antibody, interferon-γ (IFN-γ), and interleukin-2 (IL-2) were determined, and lymphocyte proliferation assays were performed
After challenge with virulent P. aeruginosa, the protective efficacy was evaluated. Following vaccination, the serum antibodies, stimulation index values, and concentrations of IFN-γ and IL-2 were significantly higher in chickens vaccinated with 100 and 200 µg vaccines than in those vaccinated with 25 and 50 µg doses (P<0.05). IFN-γ and IL-2 concentrations in chickens immunized with 100 µg vaccine were slightly higher than those in chickens immunized with 200 µg vaccine, although the difference was not statistically significant. The protective rates were 55%, 65%, 85%, and 85% with 25, 50, 100, and 200 µg of the pOPRL+pOPRF DNA vaccine, respectively.
Thus, the immune efficacy of the pOPRL+pOPRF DNA vaccine increased with an increase in immunization dose, but this does not imply that a higher dose necessarily achieves a better outcome. The optimal immunization dose of pOPRL+pOPRF DNA vaccine in chickens was 100 µg.obtained following interspecies immunizations in marmosets.thrombocytopenia which appears to be immunologically mediated. The thrombocytopenia is preceded by the formation of antibodies to the donor platelet antigen and deposition of IgG on the host's platelets. Examination of sera obtained from these animals during the course of the disease has revealed the presence of antibodies towards autologous and host-type platelets. Autologous antibody was found when thrombocytopenia was severe; upon platelet recovery, this antibody was absent or reduced in titre.
This in vivo absorption of host-specific (autologous) antibody led to detection in the serum of antibodies reactive to other members of the host species. vitamin d3 deficiency of such host-type antibodies appeared to be related to the intensity of antigenic stimulation, the amount of antibody formed and the degree of thrombocytopenia. Deposition of IgG on the host's platelets coincided with the appearance of the anti-host antibodies; whether the IgG detected on the host's platelets is exclusively cross-reactive antibody or includes also an immune complex is not yet known. Finally, the data have identified potential immunogenetic differences among members of two marmoset species with respect to platelet antigens.immunized hematooncology patients.nonhematooncology patients develop additional red blood cell (RBC) antibodies after subsequent transfusions. Check Details is unknown for hematooncology patients.
STUDY DESIGN AND METHODS: A 24-year retrospective study was conducted to determine whether RBC-immunized hematooncology patients differ from other patient cohorts regarding this strong immune response toward additional RBC challenge with clinically relevant RH, KEL, FY, JK, and MNS antigens. RESULTS: Overall, 25 of 115 immunized patients (21.7%) formed 30 additional antibodies after a median number of 7 RBC units transfused. The median interval between primary and additional antibody detection was 4 months. Diagnosis or treatment intensity did not significantly influence additional antibody development. CONCLUSION: Additional antibody formation occurs in more than 20 percent of RBC-alloimmunized hematooncology patients after subsequent transfusions and this is comparable with the frequency in other immunized patients. To avoid extensive RBC alloimmunization, preventive extended antigen matching may be considered in hematooncology patients, who have shown to be capable of antibody formation.
recipient vaccination both before and early after transplantation.immunodeficiency. We evaluated whether antibody levels can be improved by recipient vaccination on day -1 and 50 and whether the levels can be further improved by donor vaccination on day -20. A total of 85 patients were randomized or assigned to one of the following strategies of immunization with Streptococcus pneumoniae polysaccharides, Haemophilus influenzae polysaccharide-protein conjugate, tetanus toxoid (protein recall antigen) and hepatitis B surface antigen (protein neo-antigen): (1) donor on day -20, recipient on days -1, +50 and +365 (D(-20)R(-1,50,365)); (2) donor nil, recipient on days -1, +50 and +365 (D(N)R(-1,50,365)); or (3) donor nil, recipient on day +365 (D(N)R(365)). For H.